Incidence versus prevalence modeling in pharmacoeconomics

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 2, Issue 5, 2002, Pages 435-442

  Shaya, Fadia T ^a   Mullins, C Daniel ^a   Wong, Winston ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Budget impact models; Cost projections; Cost effectiveness; Epiconomics; Epidemiology; Formulary; Incidence; Pharmacoeconomics; Pharmacoepidemiology; Prevalence

Indexed keywords

ACUTE DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE COURSE; EPIDEMIOLOGY; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; PHARMACOECONOMICS; PREDICTION; PREVALENCE; REVIEW; STANDARDIZATION; SURVIVAL RATE;

EID: 0036799552     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.2.5.435     Document Type: Review

References (39)

1. Scitovsky AA. Estimating the direct cost of illness. Mil, Mem. Fund Quart. 60, 463-491 (1982).
2. Hodgson TA. The state of the art of cost-of-illness estimates. Advances Health Econ. Health Serv. Res. 4, 129-164 (1983).
3. Rice D. Cost-of-illness studies: fact or fiction? Lancet 344, 1519-1520 (1994).
4. Mauskopf J. Why study pharmacoeconomics? Expert Rev. Pharmacoeconomics Outcomes Res. 1(1), 1-3 (2001).
5. Rice DP, Cooper BS. The Economic value of human life. Am. J. Pub. Health 57, 1954-1966 (1967).
6. Mishan EJ. Cost-benefit analysis, 4th ed. Unwin Hyman, Boston, MA, USA (1988).
7. Jacobs P. Cost-benefit analysis. In: The Economics of Health and Medical Care, 2nd ed. Aspen Publications, Rockville, MD, USA (1987).
8. Schelling TC. The life you save may be your own. In: Problems in Public Expenditure Analysis. Chase SB (Ed.), Brookings Institution, Washington DC, USA (1968).
9. Lilienfeld D, Stolley P. Foundations of Epidemiology 3rd ed. Oxford University Press, New York, NY, USA (1994).
10. Mullins CD, Ogilvie S. Emerging standardization in pharmacoeconomics. Clin. Therapeut. 20(6), 1194-1202 (1998).
11. Hodgson TA, Meiner MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem. Fund Q. Health Soc. 60(3), 429-462 (1982).
12. Rice DP. Estimating the cost of illness. Health Economics Series, 6. DHEW (PHS) 947-6. US Department of Health, Education and Welfare, Rockville, MD, USA (1966).
13. Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a replication and update. Healthcare Fin. Rev. 7(1), 61-80 (1985).
14. Cruze AM, Harwood HJ, Kristiansen PC et al. Economic costs to society of alcohol and drug abuse and mental illness, Research Triangle Institute, Research Triangle Park, NC, USA (1981).
15. Harwood HJ, Napolitano DM, Kristiansen P, Collins JJ. Economic Costs to Society of Alcohol and Drug Abuse and Mental Illness, Research Triangle Institute, Research Triangle Park, NC, USA (1984).
16. Hodgson TA. Annual costs of illness versus lifetime costs of illness and implications of structural change. Drug Info. J. 22, 323-341 (1988).
17. Hodgson TA, Meiners M. Guidelines for Cost of Illness Studies in the Public Health Service. Task Force on Cost of Illness Studies, US Public Health Service, Washington, DC, USA (1979).
18. Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease and stroke: a comparative analysis. Am. J Pub. Health. 70, 1249-1260 (1980).
19. Evaluation of cost-of-illness ascertainment methodology. Part 1: Concepts, issues and methodology of cost-of-illness ascertainment. Policy Analysis Inc., MI, USA. Final Report to the National Center for Health Statistics. DHHS Contract No. 233-79-2048 (Unpublished) (1981).
20. Berry RE, Boland JP. The Economic Cost of Alcohol Abuse. Free Press, New York, NY, USA (1977).
21. Luce BR. The implications of cost-effectiveness analysis of medical technology. Case study #7: allocating costs and benefits in disease prevention programs: an application to cervical cancer screening. Office of Technology Assessment, US Congress, USA (1981).
22. Fuchs V. Who Shall Live? Health, Economics and Social Choice. Basic Books, New York, NY, USA (1974).
23. McKeown T. A historical appraisal of the medical task. In: Medical History and Medical Care. McLachlan G, McKeowen T (Eds), Oxford University Press, London, UK (1971).
24. Dubos R. Man, Medicine and Environment. Praeger, New York, NY, USA (1968).
25. Illich I. Medical Nemesis, The Expropriation of Health. Pantheon Books, New York, NY, USA (1976).
26. Birnbaum H. The Cost of Catastrophic Illness, Lexington Books, Lexington, MA, USA (1978).
27. Rice DP, McKenzie EJ. Cost of Injury in the US: a Report to Congress. School of Hygiene and Public Health, The Johns Hopkins University, MD, USA (1989).
28. Anderson WD, Gunn SA. Cancer of the cervix: time interval in repeating a cytology smear. Can. J. Clin. 17, 150 (1967).
29. Walton RJ. Cervical cancer screening program. Can. Med A. J. 114, 1003 (1976).
30. Knox A. A simulation system for screening procedures: computer simulations of cervical cytology screening programmes. In: Problems and Progress in Medical Care. McLachlan EG (Ed.) Oxford University Press, London, UK (1973).
31. Galliher HP. Optimal ages for pap smear using a multistrain model of cervical cancer. (Unpublished Manuscript). Michigan Cancer Foundation, Detroit, MI, USA (1977).
32. Dickenson LE. Control of cancer of the uterine cervix by cytology screening. Gym Onc. 3(1), 1 (1975).
33. Schneider J, Twiggs L. The costs of carcinoma of the cervix. Obstet. Gyn. 40(6), 851 (1972).
34. Department of Health, Education and Welfare, Disease Control Programs: Cancer. DHEW publication No. 1966-3, US Government Printing Office, Washington, DC, USA (1966).
35. Shaya FT, Mullins CD, Wong W. Incidence or prevalence: implications for formulary decision-making. Proceedings of the Seventh Annual International Meeting, International Society for Pharmacoeconomic; and Outcomes Research. Crystal City, VA, USA, May 19-22 (2002).
36. Gricar J, Langley P, Lyles A et al. A format for submission of clinical and economic evaluation data in support of formulary consideration by managed healthcare systems in the United States. Academy Managed Care Pharm. (2000).
37. Andrade SE, Gurwitz JH. Pharmacoepidemiology and the elderly. In: Drugs and the older population. Crome P, Ford G (Eds), Imperial College Press, London, UK, Distributed by World Scientific Publishing Co: River Edge, NJ, USA (2000).
38. Scitovsky AA. Estimating the direct cost of illness. Mil. Mem. Fund Quart. 60, 463-491 (1982).
39. Hodgson TA. The state of the art of cost-of-illness estimates. Advances Health Econ. Health Serv. Res. 4, 129-164 (1983).